Molecular Partners AG - ADR

-0.12 (-1.70%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)250.86M
Current PE2.14
Forward PE 1.98
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$4.52 Million
Adjusted EPS-$0.66
See more estimates
10-Day MA$6.76
50-Day MA$6.44
200-Day MA$10.07
See more pivots

Molecular Partners AG - ADR Stock, NASDAQ:MOLN

Wagistrasse 14, Schlieren, Schlieren, Zurich 8952
Phone: +41.44.755.77.00
Number of Employees: 177


Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Pl??ckthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.